Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020
October 19 2020 - 9:00AM
Royalty Pharma (Nasdaq: RPRX) today announced that it will report
its third quarter 2020 financial results on Wednesday, November 11,
2020 before the U.S. financial markets open. The company will host
a conference call and simultaneous webcast at 8:00 a.m. Eastern
Time that day.
Conference Call Information
The conference call can be accessed live over the
phone by dialling (833) 519-1253, or for international callers by
dialling (914) 800-3826. The passcode to access the conference call
is 8067315.
A live webcast may be accessed from the “Investors”
page of the company’s website at
https://www.royaltypharma.com/investors/news-and-events/events. A
replay of the conference call and webcast will be archived on the
company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest
buyer of biopharmaceutical royalties and a leading funder of
innovation across the biopharmaceutical industry, collaborating
with innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’
Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three
development-stage product candidates.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-2295ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024